Latest Data on IO Combinations Will Be Announced at the IO Combinations 360° Conference October 1-2, 2020

News Image

“I look forward to discussing with and hearing from leaders in the immunotherapy field regarding advancements ranging from cell and gene therapy, IO biomarkers and science driven combinations“ – Dr Theresa LaValle, Parker Institute of Cancer Immunotherapy.

The Conference Forum is presenting the 5th annual IO Combinations 360° Summit on October 1-2, 2020 virtually. Leaders in the IO Community representing biotech, pharma, academia, cancer research organizations, regulatory and investments convene to present the latest data and advancements for IO Combinations.

“What makes the 5th annual IO Combinations 360° extraordinary is the leadership from across science, clinical and business communities, coming together to share cutting-edge data and advancements driving the field,” said Kate Woda, Director, IO Combinations 360°.

Immunobiology pioneer Dr Ronald Germain, Chief, Laboratory of Immune System Biology and Director, Center for Advanced Tissue Imaging, National Institute of Allergy and Infectious Diseases at the NCI will deliver the opening keynote, providing a detailed cellular and functional analysis of the tumor microenvironment in the context of immunotherapy using highly multiplexed imaging and machine learning.

The financial keynote is delivered by expert analyst, Edward Tenthoff, Managing Director, Senior Biotech Analyst, Piper Sandler & Co, where he will provide an evaluation and forecast of the IO combination landscape.

The 2020 guest keynote is cancer veteran Steve Hamilton, who will share his clinical trial journey with an IO vaccine involving the MAGE-A3 protein paired with IL-2.

Dr Omid Hamid, The Angeles Clinic and Research Institute, Dr Alexandra Snyder, Merck Research Labs, Dr James Gulley, National Cancer Institute and Dr Raluca Verona, Janssen are co-chairing. Other distinguished speakers including:

  • Jose Baselga, MD, PhD, AstraZeneca
  • Raphaël F Rousseau, MD, PhD, Gritstone Oncology
  • Alexandra Snyder, MD, Merck Research Labs
  • Kristen Hege, MD, BMS
  • Stephen Baylin, MD, Johns Hopkins University
  • Eytan Ruppin, MD, PhD, National Cancer Institute
  • Mary Antonysamy, PhD, GSK
  • Christina Derluth, MD, Seattle Genetics
  • Alex Franzusoff, PhD, PACT Pharma
  • Dmitriy Zamarin MD, PhD, Memorial Sloan Kettering Cancer Center
  • Saul Priceman, PhD, City of Hope
  • Mark O’Hara, MD, University of Pennsylvania

IO Combinations 360° is divided into the following seven plenary discussions: Discovery and Preclinical Science, Translational Science and Emerging Biomarkers, Clinical Operations and Development, Next Generation Cell Therapy, Business Developments, and Emerging Technologies.

“I look forward to discussing with and hearing from leaders in the immunotherapy field regarding advancements ranging from cell and gene therapy, IO biomarkers and science driven combinations, “ said Dr Theresa LaValle, VP, Translational Medicine and Regulatory Affairs, Parker Institute of Cancer Immunotherapy.

For full event details on IO Combinations 360°, click here.

About IO Combinations 360˚

IO Combinations 360˚ is a two-day conference focused on the combinations used in immunotherapy to treat various forms of cancer. IO Combinations 360° was born from the Conference Forum’s Immuno-Oncology 360° event as the need for a more focused program on combinations became increasingly clear with the enormous increase in overall investment.

About the Conference Forum

The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, exchange of ideas and solutions among peers, as well as providing high quality networking.

Share article on social media or email:

Leave a Reply